Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2023 -- Impel Pharmaceuticals , a commercial-stage pharmaceutical company developing... | April 11, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Phoenix ,Arizona ,American ,Melyssa Weible ,Jennifer Robblee ,Zubair Ahmed ,Alexander Feoktistov ,Sutapa Ray ,Elixir Health Public Relations ,Impel Pharmaceuticals ,American Academy Of Neurology ,Synergy Integrative Headache Center ,Barrow Neurological Institute ,Impel Pharmaceuticals Inc ,Exchange Commission ,Sectional Survey Of Prevailing Opinions ,American Academy ,Annual Meeting ,Cross Sectional Survey ,Prevailing Opinions ,Drug Interactions Between ,Migraine Management Using ,Model Based Approach ,Concomitant Erenumab ,Migraine Patients ,Cleveland Clinic ,Concomitant Triptan ,Precision Olfactory Delivery ,Securities Litigation Reform Act ,Impel Pharmaceuticals Inc Stock Exchange ,News ,Information ,Press Release ,Highlights ,Nclude ,Multiple ,Presentations ,Ddressing ,Safety ,End ,Efficacy ,F ,Pril ,023 ,Campel ,Pharmaceuticals ,Harmaceutical ,Ompany Impl Us45258k1097 ,